VP of Human Resources, Carol Summersgill;
VP of Clinical Development, Dr. Ahmed Elkashef
PHOENIX, Jan. 30, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the addition of two new executives to its senior management team:
- Carol L. Summersgill as vice president of human resources
- Ahmed Elkashef, M.D., as vice president of clinical development
“Carol and Ahmed bring an array of talent and experience in their respective fields of expertise that will contribute significantly to the company’s transformation,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “They will be instrumental in supporting the execution of our strategic priorities and the realization of our compelling vision.”
Carol Summersgill, VP of Human Resources
Ms. Summersgill joins INSYS with more than 20 years of HR leadership experience at public and private companies in the manufacturing and retail sectors. Most recently the chief human resources officer at Libbey, Inc., a global leader in tableware, she previously led HR at Philosophy, Inc., a biotech health and beauty products company, and Therma-Tru Doors, Inc., a subsidiary of the global home and security company Fortune Brands.
Ms. Summersgill started her career at Whirlpool Corp., where she directed HR and leadership development for the global home appliance company in North America. She holds a B.S. in business from Arizona State University and an M.B.A. from Indiana University.
Ahmed Elkashef, M.D., VP of Clinical Development
Dr. Elkashef brings to INSYS more than 30 years of clinical practice and research experience. A psychiatrist by training, he served for more than a decade at the National Institute on Drug Abuse (N.I.D.A.), which is part of the National Institutes of Health (N.I.H.), ultimately as a clinical trials branch chief. Most recently, he has served as director of research at the U.A.E.’s National Rehabilitation Center since 2010. Earlier in his career, he served as a senior staff fellow at the N.I.H.’s National Institute on Mental Health (N.I.M.H.) as a schizophrenia researcher.
In connection with his extensive research experience, Dr. Elkashef has contributed as an author to dozens of peer-reviewed journal articles and has been recognized with a variety of medical and academic awards. He completed his residency in psychiatry at the W.S. Hall Psychiatric Institute at University of South Carolina in Columbia, S.C., and at the University of Maryland Medical School in Baltimore, Md. His teaching experience includes 10 years as an assistant clinical professor of psychiatry at George Washington University in Washington, D.C.
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
|CONTACT:||Corporate Communications||Investor Relations|
|Joe McGrath||Jackie Marcus or Chris Hodges|
|INSYS Therapeutics||Alpha IR Group|